Roche reports positive data from SMA treatment trial
Roche has reported positive data from the dose finding Part I FIREFISH study of Evrysdi (risdiplam) in infants with symptomatic…
Roche has reported positive data from the dose finding Part I FIREFISH study of Evrysdi (risdiplam) in infants with symptomatic…
Israel’s Rambam Medical Health Care Campus and Ziv Medical Center researchers have begun a Phase II clinical trial of Constant…
Stealth BioTherapeutics has completed enrolment in the Phase II ReCLAIM-2 study (SPIAM-202) of its lead product candidate, elamipretide, in patients with dry age-related macular degeneration…
NeuroRx has reported that the Phase IIb/III trial of Zyesami (aviptadil, previously RLF-100) showed multidimensional benefit in treating respiratory failure in critically ill Covid-19 patients.…
Yale School of Medicine has announced a randomised clinical trial led by the Yale Cardiovascular Research Group (YCRG) to study…
Specialty biopharmaceutical company RedHill Biopharma is set to expand its global Phase II/III study of opaganib in patients with severe…
Speciality biopharmaceutical company Adamis Pharmaceuticals is set to proceed with the Phase II/III study of Tempol (MBM-02) for treating Covid-19.…
Biotechnology company Amyris has reported positive preliminary results in a pre-clinical study of its ribonucleic acid (RNA) vaccine platform for…
Biopharmaceutical company NovalGen has entered a strategic partnership with contract development and manufacturing organisation HALIX to manufacture clinical trial materials.…
Perception Neuroscience has reported positive data from its first Phase 1 clinical study of PCN-101 (R-ketamine) in healthy adult participants.…
UKONIQ™ (umbralisib) is the first and only oral, dual inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1…
In the past few months, two new warehouses were erected and put into operation on the IKA premises. IKA continues…
The global MedTech outsourcing market has ballooned as businesses look for ways to improve patient care while streamlining their own…